Core Scientific (CORZ) Financials

$10.74 +0.05 (+0.47%)

Closing price 04:00 PM Eastern

Extended Trading

$10.61 -0.13 (-1.21%)

As of 07:59 PM Eastern

Annual Income Statements for Core Scientific

This table shows Core Scientific's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Net Income / (Loss) Attributable to Common Shareholders	-1,315	-246	-2,146	47	-18
Consolidated Net Income / (Loss)	-1,315	-246	-2,146	47	-12
Net Income / (Loss) Continuing Operations	-1,315	-246	-2,146	47	-18
Total Pre-Tax Income	-1,314	-246	-2,163	63	-12
Total Operating Income	-19	8.96	-2,110	131	-6.33
Total Gross Profit	121	123	8.40	239	9.39
Total Revenue	511	502	640	544	54
Operating Revenue	511	502	640	544	54
Total Cost of Revenue	390	379	632	306	51
Operating Cost of Revenue	390	379	632	306	51
Total Operating Expenses	140	114	2,118	107	16
Selling, General & Admin Expense	110	94	213	60	15
Marketing Expense	9.97	7.02	13	4.06	1.77
Research & Development Expense	12	7.18	27	7.67	5.27
Other Operating Expenses / (Income)	3.81	0.03	0.00	0.00	-
Impairment Charge	0.00	4.41	1,881	37	0.00
Other Special Charges / (Income)	4.21	1.96	-16	-2.06	-5.88
Total Other Income / (Expense), net	-1,295	-255	-54	-68	-5.88
Interest Expense	0.49	-20	0.29	8.02	1.33
Interest & Investment Income	-37	-86	-97	-44	-4.44
Other Income / (Expense), net	-1,257	-189	43	-16	-0.11
Income Tax Expense	0.86	0.68	-17	16	0.00
Basic Earnings per Share	($4.39)	($0.65)	($6.30)	$0.23	($0.14)
Weighted Average Basic Shares Outstanding	255.83M	379.86M	340.65M	207.26M	157.60M
Diluted Earnings per Share	($4.39)	($0.65)	($6.30)	$0.20	($0.14)
Weighted Average Diluted Shares Outstanding	255.83M	379.86M	340.65M	233.31M	157.60M
Weighted Average Basic & Diluted Shares Outstanding	294.12M	177.60M	373.80M	0.00	-

This table shows Core Scientific's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	581	-266	-455	-805	211	-196	-41	-9.26	-0.39	-435	-435
Consolidated Net Income / (Loss)	581	-266	-455	-805	211	-196	-41	-9.26	-0.39	-435	-435
Net Income / (Loss) Continuing Operations	581	-266	-455	-805	211	-196	-41	-9.26	-0.39	-435	-435
Total Pre-Tax Income	581	-265	-455	-805	211	-195	-41	-9.13	-0.28	-456	-424
Total Operating Income	-43	-40	-41	6.58	55	3.93	-12	9.47	7.60	-636	-401
Total Gross Profit	8.21	4.76	-0.16	39	78	39	15	37	32	-47	-27
Total Revenue	80	94	95	141	180	142	113	127	121	121	163
Operating Revenue	80	94	95	141	180	142	113	127	121	121	163
Total Cost of Revenue	71	90	96	102	102	103	97	90	89	168	190
Operating Cost of Revenue	71	90	96	102	102	103	97	90	89	168	190
Total Operating Expenses	51	44	41	32	23	35	27	27	24	589	374
Selling, General & Admin Expense	40	36	34	26	14	24	24	24	22	39	43
Other Operating Expenses / (Income)	11	0.26	0.21	1.12	2.22	0.03	0.00	0.00	0.00	-	-
Other Special Charges / (Income)	0.01	0.15	0.51	-0.27	3.82	3.80	-0.02	-0.76	-1.06	-4.32	-11
Total Other Income / (Expense), net	623	-225	-414	-811	156	-199	-29	-19	-7.89	180	-23
Interest Expense	0.00	-	0.32	0.12	0.05	1.07	-0.37	0.00	-21	0.29	0.00
Interest & Investment Income	2.19	-1.14	-7.07	-15	-14	-84	-2.20	0.04	-0.16	-22	-26
Other Income / (Expense), net	621	-224	-407	-796	170	-114	-27	-19	-28	202	3.17
Income Tax Expense	0.21	0.38	0.13	0.14	0.21	0.34	0.11	0.13	0.10	-21	11
Basic Earnings per Share	$1.44	$0.38	($1.17)	($4.51)	$0.91	($0.52)	($0.11)	($0.02)	$0.00	($1.06)	($1.23)
Weighted Average Basic Shares Outstanding	315.19M	255.83M	292.49M	178.51M	230.95M	379.86M	382.48M	375.78M	375.42M	340.65M	354.20M
Diluted Earnings per Share	$1.25	$0.51	($1.17)	($4.51)	$0.78	($0.52)	($0.11)	($0.02)	$0.00	($1.06)	($1.23)
Weighted Average Diluted Shares Outstanding	363.31M	255.83M	292.49M	178.51M	282.53M	379.86M	382.48M	375.78M	375.42M	340.65M	354.20M
Weighted Average Basic & Diluted Shares Outstanding	297.82M	294.12M	279.25M	258.22M	177.78M	177.60M	386.02M	382.61M	376.57M	373.80M	374.53M

This table details how cash moves in and out of Core Scientific's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Net Change in Cash & Equivalents	767	17	-79	123	1.81
Net Cash From Operating Activities	43	65	205	-57	-24
Net Cash From Continuing Operating Activities	43	65	205	-57	-24
Net Income / (Loss) Continuing Operations	-1,315	-246	-2,146	47	-12
Consolidated Net Income / (Loss)	-1,315	-246	-2,146	47	-12
Depreciation Expense	113	96	225	33	9.40
Amortization Expense	11	1.19	7.97	1.37	1.30
Non-Cash Adjustments To Reconcile Net Income	1,264	47	2,058	-75	4.95
Changes in Operating Assets and Liabilities, net	-30	167	60	-64	-27
Net Cash From Investing Activities	-95	-3.00	-591	-424	-15
Net Cash From Continuing Investing Activities	-95	-3.00	-591	-425	-15
Purchase of Property, Plant & Equipment	-95	-17	-384	0.00	0.00
Sale of Property, Plant & Equipment	0.00	14	0.00	0.00	-
Divestitures	0.00	0.00	11	-	-
Other Investing Activities, net	0.00	0.00	-218	-59	-1.48
Net Cash From Financing Activities	820	-45	306	604	41
Net Cash From Continuing Financing Activities	820	-45	306	604	41
Repayment of Debt	-315	-45	-113	-49	-7.10
Repurchase of Common Equity	0.00	0.00	-32	-	0.00
Issuance of Debt	1,078	0.00	261	671	45
Issuance of Common Equity	55	0.00	0.00	-	-
Other Financing Activities, net	1.50	0.00	190	-18	2.64
Cash Interest Paid	29	4.71	86	38	2.90
Cash Income Taxes Paid	-0.16	-0.37	5.76	9.62	0.00

This table details how cash moves in and out of Core Scientific's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-138	583	157	-17	45	5.77	-13	7.47	17	15	-103
Net Cash From Operating Activities	-41	14	5.71	1.20	22	22	5.43	18	20	116	-52
Net Cash From Continuing Operating Activities	-41	14	5.71	1.20	22	22	5.43	18	20	116	-52
Net Income / (Loss) Continuing Operations	581	-266	-455	-805	211	-196	-41	-9.26	-0.39	-435	-435
Consolidated Net Income / (Loss)	581	-266	-455	-805	211	-196	-41	-9.26	-0.39	-435	-435
Depreciation Expense	20	26	29	29	29	31	24	20	20	69	65
Amortization Expense	4.41	4.51	2.29	2.45	1.43	0.49	0.23	0.27	0.20	1.37	2.57
Non-Cash Adjustments To Reconcile Net Income	-662	225	431	807	-199	26	15	14	-7.76	356	390
Changes in Operating Assets and Liabilities, net	17	24	-1.46	-33	-20	159	7.52	-7.58	7.81	124	-74
Net Cash From Investing Activities	-93	-29	-31	-3.18	-32	2.36	-2.87	-0.62	-1.87	-139	-5.66
Net Cash From Continuing Investing Activities	-93	-29	-31	-3.18	-32	2.36	-2.87	-0.62	-1.87	-139	-5.66
Purchase of Property, Plant & Equipment	-88	-29	-31	-3.14	-32	-12	-2.87	-0.95	-1.54	-140	-5.22
Acquisitions	-5.00	-	-	-	-	-	-	-	-	-	-
Net Cash From Financing Activities	-4.20	598	182	-15	54	-18	-15	-9.95	-1.02	38	-45
Net Cash From Continuing Financing Activities	-4.20	598	182	-15	54	-18	-15	-9.95	-1.02	38	-45
Repayment of Debt	-3.96	-15	-271	-11	-17	-22	-12	-9.95	-1.02	14	-78
Issuance of Debt	0.00	610	448	-	20	-	-	-	0.00	45	-0.08
Issuance of Common Equity	0.00	-	-	-	55	-	-	-	0.00	-	-199
Other Financing Activities, net	-0.24	2.97	6.01	-4.10	-3.38	3.41	-3.41	-	0.00	11	231

This table presents Core Scientific's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Total Assets	1,599	712	808	2,439	0.02
Total Current Assets	904	97	85	757	0.00
Cash & Equivalents	836	50	16	118	0.00
Restricted Cash	0.78	19	36	14	-
Accounts Receivable	1.03	1.00	0.26	1.68	-
Other Current Assets	66	26	0.72	593	-
Plant, Property, & Equipment, net	556	585	691	0.00	0.00
Total Noncurrent Assets	139	30	31	1,682	0.02
Other Noncurrent Operating Assets	139	30	30	618	0.02
Total Liabilities & Shareholders' Equity	1,599	712	808	2,439	0.02
Total Liabilities	2,419	1,309	1,217	1,053	0.00
Total Current Liabilities	135	488	187	320	0.00
Short-Term Debt	16	124	36	104	-
Accounts Payable	19	155	54	12	0.00
Accrued Expenses	69	180	18	68	0.00
Current Deferred Revenue	18	9.83	78	136	-
Other Current Liabilities	12	20	0.77	0.00	-
Total Noncurrent Liabilities	2,284	821	1,030	733	0.00
Long-Term Debt	1,074	684	0.00	652	-
Capital Lease Obligations	98	37	0.72	62	-
Other Noncurrent Operating Liabilities	1,113	99	1,030	19	0.00
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-820	-597	-409	1,341	0.01
Total Preferred & Common Equity	-820	-597	-409	1,341	0.01
Preferred Stock	0.00	0.00	-	-	0.00
Total Common Equity	-820	-597	-409	1,341	0.01
Common Stock	2,915	1,823	1,764	1,380	0.03
Retained Earnings	-3,735	-2,420	-2,174	-27	-0.01

This table presents Core Scientific's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	1,625	922	761	814	705	751	760	1,404
Total Current Assets	833	278	118	143	135	111	100	214
Cash & Equivalents	698	253	96	98	42	58	47	30
Restricted Cash	0.78	0.78	0.98	16	22	19	22	8.10
Accounts Receivable	1.02	6.24	4.68	1.11	1.11	1.26	0.18	3.07
Other Current Assets	133	18	16	28	34	33	31	173
Plant, Property, & Equipment, net	650	550	550	576	547	608	628	1,156
Total Noncurrent Assets	142	94	94	95	23	32	32	34
Other Noncurrent Operating Assets	142	94	94	93	21	29	30	33
Total Liabilities & Shareholders' Equity	1,625	922	761	814	705	751	760	1,404
Total Liabilities	1,807	1,651	1,845	1,132	1,124	1,143	1,169	1,331
Total Current Liabilities	196	77	75	138	313	187	215	1,289
Short-Term Debt	16	18	18	23	128	28	36	978
Accounts Payable	6.33	6.50	8.49	16	46	54	50	44
Accrued Expenses	95	32	29	68	56	41	59	102
Current Deferred Revenue	61	9.94	7.91	9.25	63	64	70	87
Other Current Liabilities	17	10	11	21	20	0.42	0.60	78
Total Noncurrent Liabilities	1,611	1,575	1,771	994	812	956	954	42
Long-Term Debt	1,072	475	527	557	680	0.05	-	0.00
Capital Lease Obligations	95	65	68	70	37	1.03	1.06	0.00
Other Noncurrent Operating Liabilities	445	1,035	1,176	368	95	955	953	42
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-182	-729	-1,084	-319	-419	-392	-409	73
Total Preferred & Common Equity	-182	-729	-1,084	-319	-419	-392	-409	73
Preferred Stock	0.00	0.00	0.00	0.00	-	-	-	-
Total Common Equity	-182	-729	-1,084	-319	-419	-392	-409	73
Common Stock	2,973	2,740	1,931	1,891	1,806	1,791	1,777	1,739
Retained Earnings	-3,155	-3,470	-3,014	-2,210	-2,225	-2,183	-2,185	-1,739

This table displays calculated financial ratios and metrics derived from Core Scientific's official financial filings.

Metric	2024	2023	2022	2021	2020
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Growth Metrics	-	-	-	-	-
Revenue Growth	1.65%	-21.54%	17.60%	904.71%	0.00%
EBITDA Growth	-1,298.35%	95.50%	-1,320.57%	3,420.42%	0.00%
EBIT Growth	-610.67%	91.31%	-1,889.85%	1,893.46%	0.00%
NOPAT Growth	-314.22%	100.42%	-1,597.16%	2,327.02%	0.00%
Net Income Growth	-433.50%	88.52%	-4,636.52%	487.61%	0.00%
EPS Growth	-575.38%	89.68%	-3,250.00%	242.86%	0.00%
Operating Cash Flow Growth	-34.12%	-68.27%	461.66%	-138.73%	0.00%
Free Cash Flow Firm Growth	206.23%	-158.53%	151.71%	0.00%	0.00%
Invested Capital Growth	-361.96%	142.17%	-120.49%	14,197,256.16%	0.00%
Revenue Q/Q Growth	-8.52%	4.29%	-21.99%	0.00%	0.00%
EBITDA Q/Q Growth	-15.51%	77.58%	-35.42%	0.00%	0.00%
EBIT Q/Q Growth	-13.68%	64.30%	-34.39%	0.00%	0.00%
NOPAT Q/Q Growth	-178.28%	101.42%	-53.83%	0.00%	0.00%
Net Income Q/Q Growth	-5.61%	49.25%	-30.00%	0.00%	0.00%
EPS Q/Q Growth	19.00%	45.38%	-26.25%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	-15.55%	-59.15%	3.14%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	-17.43%	-343.69%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	-10.28%	-45.09%	-141.92%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-
Gross Margin	23.71%	24.57%	1.31%	43.87%	17.33%
EBITDA Margin	-225.72%	-16.41%	-286.28%	27.58%	7.87%
Operating Margin	-3.76%	1.78%	-329.46%	24.15%	-11.67%
EBIT Margin	-249.98%	-35.75%	-322.70%	21.20%	-11.88%
Profit (Net Income) Margin	-257.50%	-49.06%	-335.20%	8.69%	-22.52%
Tax Burden Percent	100.07%	100.28%	99.21%	75.01%	100.00%
Interest Burden Percent	102.94%	136.84%	104.70%	54.64%	189.62%
Effective Tax Rate	0.00%	0.00%	0.00%	24.99%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	-179.19%	9.52%	-30,334.93%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	-378.53%	-5.42%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	-260.48%	-2.69%	0.00%
Return on Equity (ROE)	185.59%	48.99%	-439.67%	6.83%	0.00%
Cash Return on Invested Capital (CROIC)	0.00%	-333.65%	0.00%	-190.48%	0.00%
Operating Return on Assets (OROA)	-110.48%	-23.64%	-127.29%	9.47%	-42,913.33%
Return on Assets (ROA)	-113.81%	-32.44%	-132.22%	3.88%	-81,373.33%
Return on Common Equity (ROCE)	185.59%	48.99%	-419.64%	6.61%	0.00%
Return on Equity Simple (ROE_SIMPLE)	160.33%	41.29%	524.33%	3.53%	0.00%
Net Operating Profit after Tax (NOPAT)	-13	6.27	-1,477	99	-4.43
NOPAT Margin	-2.63%	1.25%	-230.62%	18.11%	-8.17%
Net Nonoperating Expense Percent (NNEP)	230.95%	66.45%	199.34%	14.94%	0.00%
Return On Investment Capital (ROIC_SIMPLE)	-3.65%	2.52%	396.55%	-	-
Cost of Revenue to Revenue	76.29%	75.43%	98.69%	56.13%	93.98%
SG&A Expenses to Revenue	21.63%	18.69%	33.31%	11.11%	26.86%
R&D to Revenue	2.32%	1.43%	4.21%	1.41%	9.73%
Operating Expenses to Revenue	27.47%	22.79%	330.77%	19.72%	29.00%
Earnings before Interest and Taxes (EBIT)	-1,277	-180	-2,066	115	-6.44
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-1,153	-82	-1,833	150	4.27
Valuation Ratios	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	0.00	20,547.95
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	20,547.95
Price to Revenue (P/Rev)	7.68	0.00	0.00	0.00	5.54
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	20,547.95
Enterprise Value to Revenue (EV/Rev)	8.37	0.00	0.00	0.00	5.54
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	70.32
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	99.65	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	6.74	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-
Debt to Equity	-1.45	-1.42	-0.09	0.59	0.00
Long-Term Debt to Equity	-1.43	-1.21	0.00	0.52	0.00
Financial Leverage	-0.80	-0.76	0.69	0.50	0.00
Leverage Ratio	-1.63	-1.51	3.33	1.76	1.03
Compound Leverage Factor	-1.68	-2.07	3.48	0.96	1.95
Debt to Total Capital	322.91%	339.97%	-9.93%	37.14%	0.00%
Short-Term Debt to Total Capital	4.43%	49.99%	-9.73%	4.74%	0.00%
Long-Term Debt to Total Capital	318.48%	289.98%	-0.19%	32.40%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	2.02%	0.00%
Common Equity to Total Capital	-222.91%	-239.97%	109.93%	60.84%	100.00%
Debt to EBITDA	-1.03	-10.26	-0.02	5.45	0.00
Net Debt to EBITDA	-0.30	-9.41	0.01	4.58	0.00
Long-Term Debt to EBITDA	-1.02	-8.75	0.00	4.76	0.00
Debt to NOPAT	-88.42	134.82	-0.03	8.30	0.00
Net Debt to NOPAT	-26.13	123.71	0.01	6.97	0.00
Long-Term Debt to NOPAT	-87.21	115.00	0.00	7.24	0.00
Altman Z-Score	-4.04	0.00	0.00	0.00	452,195.72
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	4.56%	3.21%	0.00%
Liquidity Ratios	-	-	-	-	-
Current Ratio	6.72	0.20	0.46	2.36	0.00
Quick Ratio	6.22	0.11	0.09	0.37	0.00
Cash Flow Metrics	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	635	-597	1,021	-1,974	0.00
Operating Cash Flow to CapEx	45.06%	2,173.36%	53.44%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	1,303.17	0.00	3,556.62	-246.28	0.00
Operating Cash Flow to Interest Expense	88.08	0.00	714.94	-7.08	-17.83
Operating Cash Flow Less CapEx to Interest Expense	-107.38	0.00	-622.97	-7.08	-17.83
Efficiency Ratios	-	-	-	-	-
Asset Turnover	0.44	0.66	0.39	0.45	3,612.87
Accounts Receivable Turnover	504.12	798.73	660.46	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.89	0.79	0.00	0.00	0.00
Accounts Payable Turnover	4.48	3.64	19.37	0.00	0.00
Days Sales Outstanding (DSO)	0.72	0.46	0.55	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	81.51	100.36	18.85	0.00	0.00
Cash Conversion Cycle (CCC)	-80.79	-99.91	-18.29	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-
Invested Capital	-469	179	-425	2,073	0.01
Invested Capital Turnover	-3.52	-4.09	0.78	0.53	3,711.85
Increase / (Decrease) in Invested Capital	-648	604	-2,497	2,073	0.00
Enterprise Value (EV)	4,275	0.00	0.00	0.00	300
Market Capitalization	3,924	0.00	0.00	0.00	300
Book Value per Share	($2.94)	($1.55)	($1.09)	$31.10	$0.00
Tangible Book Value per Share	($2.94)	($1.55)	($1.10)	$6.43	$0.00
Total Capital	368	249	-372	2,204	0.01
Total Debt	1,188	846	37	819	0.00
Total Long-Term Debt	1,172	721	0.72	714	0.00
Net Debt	351	776	-15	687	0.00
Capital Expenditures (CapEx)	95	3.00	384	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-51	-337	-118	409	-0.00
Debt-free Net Working Capital (DFNWC)	786	-267	-65	541	-0.00
Net Working Capital (NWC)	769	-391	-102	436	-0.00
Net Nonoperating Expense (NNE)	1,302	253	670	51	7.78
Net Nonoperating Obligations (NNO)	351	776	-15	687	0.00
Total Depreciation and Amortization (D&A)	124	97	233	35	11
Debt-free, Cash-free Net Working Capital to Revenue	-10.04%	-67.03%	-18.38%	75.12%	0.00%
Debt-free Net Working Capital to Revenue	153.85%	-53.15%	-10.22%	99.31%	0.00%
Net Working Capital to Revenue	150.66%	-77.91%	-15.88%	80.13%	0.00%
Earnings Adjustments	-	-	-	-	-
Adjusted Basic Earnings per Share	($4.39)	($0.65)	($6.30)	($0.83)	$0.00
Adjusted Weighted Average Basic Shares Outstanding	255.83M	379.86M	340.65M	316.24M	0.00
Adjusted Diluted Earnings per Share	($4.39)	($0.65)	($6.30)	($0.83)	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	255.83M	379.86M	340.65M	316.24M	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	($0.83)	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	294.12M	177.60M	373.80M	8.50M	0.00
Normalized Net Operating Profit after Tax (NOPAT)	-10	11	-171	125	-8.55
Normalized NOPAT Margin	-2.05%	2.14%	-26.74%	22.96%	-15.77%
Pre Tax Income Margin	-257.34%	-48.93%	-337.87%	11.58%	-22.52%
Debt Service Ratios	-	-	-	-	-
EBIT to Interest Expense	-2,621.33	0.00	-7,199.64	14.40	-4.83
NOPAT to Interest Expense	-27.59	0.00	-5,145.25	12.30	-3.32
EBIT Less CapEx to Interest Expense	-2,816.80	0.00	-8,537.55	14.40	-4.83
NOPAT Less CapEx to Interest Expense	-223.06	0.00	-6,483.16	12.30	-3.32
Payout Ratios	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	-1.47%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Core Scientific's official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-55.64%	-33.50%	-15.54%	11.18%	49.05%	17.05%	-30.55%	-22.60%	-37.33%	-59.82%	43.69%
EBITDA Growth	135.99%	-196.78%	-2,726.82%	-6,645.19%	42,747.75%	78.38%	95.55%	101.49%	99.83%	-414.78%	-10,126.32%
EBIT Growth	157.17%	-139.23%	-1,041.89%	-8,516.31%	1,177.34%	74.57%	90.15%	98.90%	94.81%	-557.91%	-10,176.34%
NOPAT Growth	-177.18%	-1,111.26%	-242.24%	-30.52%	936.81%	100.62%	97.00%	100.91%	128.45%	-654.42%	-8,489.92%
Net Income Growth	175.61%	-35.69%	-1,006.45%	-8,592.18%	54,401.80%	55.00%	90.54%	98.86%	99.92%	-818.68%	-2,514.66%
EPS Growth	60.26%	198.08%	-963.64%	-22,450.00%	0.00%	50.94%	91.06%	99.20%	100.00%	-524.00%	-1,657.14%
Operating Cash Flow Growth	-283.09%	-36.39%	5.13%	-93.32%	11.19%	-81.29%	110.44%	-87.55%	651.65%	5.69%	-15.35%
Free Cash Flow Firm Growth	78.78%	203.21%	6.50%	-92.92%	-122.22%	-129.28%	167.74%	201.41%	239.76%	0.00%	0.00%
Invested Capital Growth	39.33%	-361.96%	-230.43%	-29.02%	149.24%	142.17%	-67.81%	-130.95%	-119.44%	-120.49%	246.47%
Revenue Q/Q Growth	-15.74%	-1.02%	-32.42%	-21.54%	26.71%	25.71%	-11.04%	5.19%	-0.49%	-25.42%	-0.85%
EBITDA Q/Q Growth	358.20%	43.98%	45.01%	-396.69%	424.72%	-433.62%	-227.31%	2,033.22%	99.84%	-9.91%	57.51%
EBIT Q/Q Growth	319.18%	41.03%	43.31%	-450.99%	303.90%	-181.47%	-327.73%	56.11%	95.19%	-8.98%	52.14%
NOPAT Q/Q Growth	-52.90%	3.48%	-726.52%	-91.65%	1,903.52%	132.66%	-227.19%	24.56%	101.20%	-58.48%	61.61%
Net Income Q/Q Growth	318.68%	41.67%	43.44%	-482.03%	207.66%	-375.61%	-344.34%	-2,286.60%	99.91%	-0.01%	46.35%
EPS Q/Q Growth	145.10%	143.59%	74.06%	-678.21%	250.00%	-372.73%	-450.00%	0.00%	100.00%	13.82%	50.60%
Operating Cash Flow Q/Q Growth	-394.09%	141.64%	374.50%	-94.57%	2.17%	299.39%	-69.87%	-9.56%	-82.81%	322.74%	-135.94%
Free Cash Flow Firm Q/Q Growth	-120.64%	-14.16%	445.71%	121.94%	-0.68%	-188.57%	-63.72%	-31.15%	32.37%	304.90%	45.70%
Invested Capital Q/Q Growth	164.55%	-10.28%	25.15%	-361.48%	22.41%	-45.09%	174.04%	0.21%	-3.94%	-141.92%	-28.83%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	10.33%	5.05%	-0.16%	27.51%	43.18%	27.69%	13.66%	29.12%	26.34%	-38.96%	-16.65%
EBITDA Margin	758.06%	-247.38%	-437.06%	-537.15%	142.05%	-55.43%	-13.06%	9.12%	-0.50%	-300.10%	-203.64%
Operating Margin	-53.56%	-42.15%	-43.23%	4.66%	30.71%	2.77%	-10.67%	7.46%	6.30%	-524.60%	-246.89%
EBIT Margin	727.71%	-279.75%	-469.55%	-559.78%	125.13%	-77.76%	-34.73%	-7.22%	-17.31%	-357.90%	-244.94%
Profit (Net Income) Margin	730.20%	-281.35%	-477.44%	-570.44%	117.16%	-137.88%	-36.44%	-7.30%	-0.32%	-358.64%	-267.45%
Tax Burden Percent	99.96%	100.14%	100.03%	100.02%	99.90%	100.17%	100.28%	101.41%	136.62%	95.29%	102.51%
Interest Burden Percent	100.38%	100.43%	101.65%	101.89%	93.72%	177.01%	104.65%	99.61%	1.36%	105.16%	106.51%
Effective Tax Rate	0.04%	0.00%	0.00%	0.00%	0.10%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-84.61%	0.00%	0.00%	0.00%	0.00%	0.00%	-5.37%	5.65%	2.74%	-285.33%	-217.36%
ROIC Less NNEP Spread (ROIC-NNEP)	37.59%	0.00%	0.00%	0.00%	0.00%	0.00%	-9.26%	2.33%	1.71%	-282.23%	-250.14%
Return on Net Nonoperating Assets (RNNOA)	-76.69%	0.00%	0.00%	0.00%	0.00%	0.00%	45.11%	93.18%	2.65%	-194.21%	-639.58%
Return on Equity (ROE)	-161.30%	185.59%	216.90%	112.58%	9.74%	48.99%	39.74%	98.83%	5.39%	-479.54%	-856.93%
Cash Return on Invested Capital (CROIC)	-64.37%	0.00%	0.00%	0.00%	-284.87%	-333.65%	36.61%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	245.16%	-123.64%	-322.14%	-426.24%	89.29%	-51.41%	-15.86%	-2.96%	-5.68%	-141.18%	-229.65%
Return on Assets (ROA)	246.00%	-124.34%	-327.55%	-434.35%	83.60%	-91.16%	-16.64%	-2.99%	-0.11%	-141.47%	-250.74%
Return on Common Equity (ROCE)	-161.30%	185.59%	216.90%	112.58%	9.74%	48.99%	39.74%	98.83%	5.39%	-457.69%	-51.36%
Return on Equity Simple (ROE_SIMPLE)	520.64%	0.00%	170.71%	76.67%	11.12%	0.00%	115.98%	224.06%	411.12%	0.00%	-2,260.76%
Net Operating Profit after Tax (NOPAT)	-43	-28	-29	4.61	55	2.75	-8.43	6.63	5.32	-445	-281
NOPAT Margin	-53.54%	-29.51%	-30.26%	3.26%	30.68%	1.94%	-7.47%	5.22%	4.41%	-367.22%	-172.82%
Net Nonoperating Expense Percent (NNEP)	-122.20%	42.18%	81.31%	346.20%	-61.81%	52.17%	3.88%	3.31%	1.03%	-3.10%	32.79%
Return On Investment Capital (ROIC_SIMPLE)	-4.25%	-7.57%	-	-	-	1.11%	-	-	-	119.57%	-
Cost of Revenue to Revenue	89.67%	95.53%	100.16%	72.49%	56.52%	72.31%	86.34%	70.88%	73.66%	138.96%	116.65%
SG&A Expenses to Revenue	50.44%	37.83%	36.03%	18.60%	7.86%	17.08%	20.82%	19.22%	18.04%	32.08%	26.66%
R&D to Revenue	0.00%	5.31%	2.98%	1.54%	1.00%	1.32%	2.00%	1.29%	1.17%	2.19%	3.81%
Operating Expenses to Revenue	63.89%	46.62%	43.06%	22.85%	12.77%	24.92%	24.32%	21.66%	20.04%	485.64%	230.24%
Earnings before Interest and Taxes (EBIT)	579	-264	-448	-790	225	-110	-39	-9.17	-21	-434	-398
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	603	-233	-417	-758	255	-79	-15	12	-0.60	-364	-331
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	5.18	7.68	5.49	2.87	1.12	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	8.63	0.00	0.00	0.00	5.36	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	6.36	8.37	6.03	3.77	2.07	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	6.71	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	17.57	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	196.14	57.71	29.40	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	99.65	66.28	42.94	17.29	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	6.74	4.38	13.11	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	-6.52	-1.45	-0.76	-0.57	-2.04	-1.42	-2.02	-0.07	-0.09	-0.09	13.39
Long-Term Debt to Equity	-6.43	-1.43	-0.74	-0.55	-1.97	-1.21	-1.71	0.00	0.00	0.00	0.00
Financial Leverage	-2.04	-0.80	-0.91	-0.32	-0.69	-0.76	-4.87	39.93	1.55	0.69	2.56
Leverage Ratio	-4.88	-1.63	-1.42	-1.02	-2.16	-1.51	-6.10	108.12	4.82	3.33	4.77
Compound Leverage Factor	-4.90	-1.64	-1.44	-1.04	-2.03	-2.67	-6.39	107.69	0.07	3.50	5.08
Debt to Total Capital	118.12%	322.91%	-325.26%	-130.06%	196.06%	339.97%	198.27%	-7.91%	-9.86%	-9.93%	93.05%
Short-Term Debt to Total Capital	1.62%	4.43%	-10.46%	-3.90%	7.04%	49.99%	30.11%	-7.62%	-9.58%	-9.73%	93.05%
Long-Term Debt to Total Capital	116.50%	318.48%	-314.80%	-126.16%	189.02%	289.98%	168.15%	-0.30%	-0.28%	-0.19%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	-18.12%	-222.91%	425.26%	230.06%	-96.06%	-239.97%	-98.27%	107.91%	109.86%	109.93%	6.95%
Debt to EBITDA	-1.47	-1.03	-0.56	-1.03	3.74	-10.26	-2.30	-0.04	-0.02	-0.02	-0.72
Net Debt to EBITDA	-0.60	-0.30	-0.30	-0.87	3.09	-9.41	-2.12	0.07	0.02	0.01	-0.69
Long-Term Debt to EBITDA	-1.45	-1.02	-0.54	-1.00	3.61	-8.75	-1.95	0.00	0.00	0.00	0.00
Debt to NOPAT	-14.44	-88.42	32.50	16.30	16.41	134.82	-1.91	-0.04	-0.03	-0.03	-1.02
Net Debt to NOPAT	-5.91	-26.13	17.72	13.72	13.53	123.71	-1.77	0.07	0.02	0.01	-0.98
Long-Term Debt to NOPAT	-14.24	-87.21	31.46	15.81	15.82	115.00	-1.62	0.00	0.00	0.00	0.00
Altman Z-Score	-0.11	-1.95	-4.89	-7.60	-1.86	0.00	0.00	0.00	0.00	0.00	0.00
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	4.56%	94.01%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.26	6.72	3.63	1.58	1.04	0.20	0.43	0.59	0.47	0.46	0.17
Quick Ratio	3.58	6.22	3.39	1.35	0.72	0.11	0.14	0.31	0.22	0.09	0.03
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-128	620	723	132	-603	-601	678	1,870	2,717	2,052	-1,002
Operating Cash Flow to CapEx	-45.90%	47.62%	18.33%	38.41%	69.52%	186.48%	189.47%	1,900.42%	1,295.78%	82.71%	-997.93%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	2,279.39	1,103.41	-12,069.80	-561.60	0.00	0.00	0.00	7,150.46	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	18.02	10.03	443.48	20.28	0.00	0.00	0.00	404.13	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	-80.32	-16.09	-194.40	9.41	0.00	0.00	0.00	-84.46	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.34	0.44	0.69	0.76	0.71	0.66	0.46	0.41	0.33	0.39	0.94
Accounts Receivable Turnover	386.74	504.12	151.83	194.02	876.10	798.73	230.49	222.52	1,659.71	660.46	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.67	0.89	1.02	0.99	0.93	0.79	0.57	0.64	0.79	0.00	0.00
Accounts Payable Turnover	31.95	4.48	15.46	12.94	11.78	3.64	9.98	12.60	18.14	19.37	28.14
Days Sales Outstanding (DSO)	0.94	0.72	2.40	1.88	0.42	0.46	1.58	1.64	0.22	0.55	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	11.43	81.51	23.62	28.22	30.99	100.36	36.57	28.97	20.13	18.85	12.97
Cash Conversion Cycle (CCC)	-10.48	-80.79	-21.21	-26.33	-30.57	-99.91	-34.99	-27.33	-19.91	-18.29	-12.97
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	303	-469	-425	-568	217	179	326	-440	-441	-425	1,013
Invested Capital Turnover	1.58	-3.52	-11.25	-1.14	-5.01	-4.09	0.72	1.08	0.62	0.78	1.26
Increase / (Decrease) in Invested Capital	85	-648	-751	-128	659	604	-687	-1,864	-2,711	-2,497	721
Enterprise Value (EV)	2,614	4,275	3,367	2,169	1,165	0.00	0.00	0.00	0.00	0.00	0.00
Market Capitalization	2,129	3,924	3,063	1,653	629	0.00	0.00	0.00	0.00	0.00	0.00
Book Value per Share	($0.62)	($2.94)	($2.82)	($6.10)	($1.79)	($1.55)	($1.09)	($1.04)	($1.09)	($1.09)	$0.20
Tangible Book Value per Share	($0.62)	($2.94)	($2.82)	($6.10)	($1.81)	($1.55)	($1.10)	($1.05)	($1.10)	($1.10)	$0.20
Total Capital	1,002	368	-172	-471	332	249	426	-364	-372	-372	1,051
Total Debt	1,183	1,188	558	613	650	846	845	29	37	37	978
Total Long-Term Debt	1,167	1,172	540	594	627	721	717	1.08	1.06	0.72	0.00
Net Debt	484	351	304	516	536	776	781	-48	-33	-15	940
Capital Expenditures (CapEx)	88	29	31	3.14	32	12	2.87	0.95	1.54	140	5.22
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-45	-51	-35	-36	-86	-337	-114	-125	-148	-118	-135
Debt-free Net Working Capital (DFNWC)	654	786	219	61	29	-267	-50	-48	-79	-65	-98
Net Working Capital (NWC)	638	769	201	43	5.18	-391	-178	-76	-115	-102	-1,075
Net Nonoperating Expense (NNE)	-623	238	426	810	-156	198	33	16	5.71	-10	154
Net Nonoperating Obligations (NNO)	484	351	304	516	536	776	745	-48	-33	-15	940
Total Depreciation and Amortization (D&A)	24	31	31	32	30	32	24	21	20	70	67
Debt-free, Cash-free Net Working Capital to Revenue	-10.91%	-10.04%	-6.18%	-6.20%	-15.27%	-67.03%	-23.57%	-23.57%	-26.07%	-18.38%	-16.50%
Debt-free Net Working Capital to Revenue	159.13%	153.85%	39.28%	10.67%	5.08%	-53.15%	-10.30%	-9.12%	-13.88%	-10.22%	-11.92%
Net Working Capital to Revenue	155.19%	150.66%	36.07%	7.48%	0.92%	-77.91%	-36.94%	-14.34%	-20.15%	-15.88%	-131.01%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.44	$0.38	($1.17)	($4.51)	$0.91	($0.52)	($0.11)	($0.02)	($0.03)	($1.06)	($1.23)
Adjusted Weighted Average Basic Shares Outstanding	315.19M	255.83M	292.49M	178.51M	230.95M	379.86M	382.48M	375.78M	375.42M	340.65M	354.20M
Adjusted Diluted Earnings per Share	$1.25	$0.51	($1.17)	($4.51)	$0.78	($0.52)	($0.11)	($0.02)	($0.03)	($1.06)	($1.23)
Adjusted Weighted Average Diluted Shares Outstanding	363.31M	255.83M	292.49M	178.51M	282.53M	379.86M	382.48M	375.78M	375.42M	340.65M	354.20M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	297.82M	294.12M	279.25M	258.22M	177.78M	177.60M	386.02M	382.61M	376.57M	373.80M	374.53M
Normalized Net Operating Profit after Tax (NOPAT)	-43	-28	-28	4.42	59	6.49	-7.97	6.89	5.32	-63	-54
Normalized NOPAT Margin	-53.54%	-29.40%	-29.89%	3.13%	32.80%	4.58%	-7.06%	5.43%	4.41%	-51.88%	-33.01%
Pre Tax Income Margin	730.46%	-280.95%	-477.30%	-570.33%	117.27%	-137.64%	-36.34%	-7.19%	-0.24%	-376.36%	-260.90%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	-1,412.42	-6,582.14	4,500.68	-103.15	0.00	0.00	0.00	-1,512.05	0.00
NOPAT to Interest Expense	0.00	0.00	-91.02	38.38	1,103.46	2.57	0.00	0.00	0.00	-1,551.41	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	-1,510.76	-6,608.27	3,862.80	-114.02	0.00	0.00	0.00	-2,000.63	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	-189.36	12.25	465.58	-8.30	0.00	0.00	0.00	-2,040.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-1.47%	0.00%

Frequently Asked Questions About Core Scientific's Financials

When does Core Scientific's fiscal year end?

According to the most recent income statement we have on file, Core Scientific's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Core Scientific's net income changed over the last 4 years?

Core Scientific's net income appears to be on an upward trend, with a most recent value of -$1.32 billion in 2024, rising from -$12.21 million in 2020. The previous period was -$246.49 million in 2023. See Core Scientific's forecast for analyst expectations on what’s next for the company.

What is Core Scientific's operating income?

Core Scientific's total operating income in 2024 was -$19.20 million, based on the following breakdown:

Total Gross Profit: $121.07 million
Total Operating Expenses: $140.27 million

How has Core Scientific revenue changed over the last 4 years?

Over the last 4 years, Core Scientific's total revenue changed from $54.19 million in 2020 to $510.67 million in 2024, a change of 842.3%.

How much debt does Core Scientific have?

Core Scientific's total liabilities were at $2.42 billion at the end of 2024, a 84.8% increase from 2023, and a 604,748,650.0% increase since 2020.

How much cash does Core Scientific have?

In the past 4 years, Core Scientific's cash and equivalents has ranged from $0.00 in 2020 to $836.20 million in 2024, and is currently $836.20 million as of their latest financial filing in 2024.

How has Core Scientific's book value per share changed over the last 4 years?

Over the last 4 years, Core Scientific's book value per share changed from 0.00 in 2020 to -2.94 in 2024, a change of -2,937,100.0%.

Related Companies

This page (NASDAQ:CORZ) was last updated on 5/30/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Core Scientific (CORZ) Financials

Frequently Asked Questions About Core Scientific's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Core Scientific (CORZ) Financials

Annual Income Statements for Core Scientific

Quarterly Income Statements for Core Scientific

Annual Cash Flow Statements for Core Scientific

Quarterly Cash Flow Statements for Core Scientific

Annual Balance Sheets for Core Scientific

Quarterly Balance Sheets for Core Scientific

Annual Metrics And Ratios for Core Scientific

Quarterly Metrics And Ratios for Core Scientific

Frequently Asked Questions About Core Scientific's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools